Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients

被引：30
|
作者：
Campo, RE [1 ]
Lalanne, R
Tanner, TJ
Jayaweera, DT
Rodriguez, AE
Fontaine, L
Kolber, MA
机构：
[1] Univ Miami, Sch Med, Div Infect Dis, Miami, FL USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
AIDS | 2005年 / 19卷 / 04期
关键词：
D O I：
10.1097/01.aids.0000161777.38438.ed
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
下载
收藏
页码：447 / 449
页数：3
相关论文
共 50 条
  • [1] Lopinavir Plasma Concentrations and Virological Outcome with Lopinavir-Ritonavir Monotherapy in HIV-1-Infected Patients
    Lopez-Cortes, Luis F.
    Ruiz-Valderas, Rosa
    Sanchez-Rivas, Elena
    Lluch, Amparo
    Gutierrez-Valencia, Alicia
    Torres-Cornejo, Almudena
    BenMarzouk-Hidalgo, Omar J.
    Viciana, Pompeyo
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (08) : 3746 - 3751
  • [2] Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)
    Osvaldo Ulises Garay
    Marie Libérée Nishimwe
    Marwân-al-Qays Bousmah
    Asmaa Janah
    Pierre-Marie Girard
    Geneviève Chêne
    Laetitia Moinot
    Luis Sagaon-Teyssier
    Jean-Luc Meynard
    Bruno Spire
    Sylvie Boyer
    PharmacoEconomics - Open, 2019, 3 : 505 - 515
  • [3] Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)
    Garay, Osvaldo Ulises
    Nishimwe, Marie Liberee
    Bousmah, Marwan-al-Qays
    Janah, Asmaa
    Girard, Pierre-Marie
    Chene, Genevieve
    Moinot, Laetitia
    Sagaon-Teyssier, Luis
    Meynard, Jean-Luc
    Spire, Bruno
    Boyer, Sylvie
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 505 - 515
  • [4] Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients
    Foudraine, NA
    Hovenkamp, E
    Notermans, DW
    Meenhorst, PL
    Klein, MR
    Lange, JMA
    Miedema, F
    Reiss, P
    AIDS, 1999, 13 (02) : 177 - 184
  • [5] Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy
    Parera, M
    Ibáñez, A
    Clotet, B
    Martinez, MA
    JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (08): : 1444 - 1451
  • [6] Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression
    Chan-Tack, KM
    Edozien, A
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (04) : 531 - 532
  • [7] Bacterial Meningitis in HIV-1-infected Patients in the Era of Highly Active Antiretroviral Therapy
    Domingo, Pere
    Suarez-Lozano, Ignacio
    Torres, Ferran
    Pomar, Virginia
    Ribera, Esteban
    Jose Galindo, Ma
    Cosin, Jaime
    Luisa Garcia-Alcalde, Ma
    Vidal, Francesc
    Lopez-Aldeguer, Jose
    Roca, Bernardino
    Gonzalez, Juan
    Lozano, Fernando
    Garrido, Myriam
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (05) : 582 - 587
  • [8] Population pharmacokinetics of lopinavir/ritonavir (LPVr) in HIV-1-infected patients
    Crommentuyn, KML
    Kappelhoff, BS
    Mulder, JW
    Mairuhu, ATA
    van Gorp, ECM
    Meenhorst, PL
    Huitema, ADR
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 609 - 610
  • [9] Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-Infected children
    Resino, S
    Galán, I
    Pérez, A
    Ramos, JT
    Bellón, JM
    Fontelos, PM
    De José, MI
    Gutiérrez, MDG
    Cabrero, E
    Muñoz-Fernández, MAM
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (05) : 398 - 406
  • [10] Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients
    Crommentuyn, KML
    Kappelhoff, BS
    Mulder, JW
    Mairuhu, ATA
    van Gorp, ECM
    Meenhorst, PL
    Huitema, ADR
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) : 378 - 389
12345